We just held our 2022 Annual General Meeting for our investors, and a few weeks ago convened our Atlas Venture Retreat – both in person for the first time in 3 years.  Kicking off each of these meetings is our

By Robert Clarke, CEO and founder of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC 2022 has been a hallmark year for Kinaset Therapeutics as we’ve continued to advance our P1b trial with our lead asset.

By Deanna Petersen, CBO of AVROBio, as part of the From the Trenches feature of LifeSciVC Gene therapy’s tremendous potential to transform the treatment of both rare and common diseases has been understood for decades. But few may appreciate how

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotechnology, especially of late, requires us to prevail over adversity to deliver for patients.  Spero, dedicated to new solutions for patients with infections,

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC As one thinks about the iconic break-up lines, it doesn’t take long to come up with: It’s not you; it’s me… I am

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC By all accounts, 2022 did not start according to plan for the biotech industry. The U.S. economy and growth stocks struggled with the

By Peter Smith, co-founder and CEO, Remix Therapeutics, as part of the From The Trenches feature of LifeSciVC One of the joys of starting a company is the ability to pro-actively define the early corporate culture and encourage its evolution

By Ivana Magovcevic-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC From academic research, patent law, business development, to being a CEO, all my experiences have taught me two things. First, one cannot do

It’s biotech armageddon out there: with massive value destruction across public stocks, it’s clearly the worst market backdrop in over 20 years. Nothing like this pullback has happened in recent memory. This is way worse than the short “sky is

By Robert Clarke, CEO of Kinaset, as part of the From The Trenches feature of LifeSciVC. Although I intend to shy away from the cult of celebrity, a recent clip from Tom Hanks resonated with me regarding the current state

By Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system by

By Deanna Petersen, CBO of AVROBIO, and Ted Tanaka, consultant with Tanaka International LLC, as part of the From The Trenches feature of LifeSciVC Imagine yourself setting out to do business in Japan. You step off the plane, check into